Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594630 · ClinicalTrials.gov registry record · Early Phase 1
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
A Early Phase 1 study of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03594630 is a Early Phase 1 study of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 120 participants, roughly in line with the 117-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03594630, a Early Phase 1 study of Rectal Adenocarcinoma and Stage III Rectal Cancer AJCC v8, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer. Active surveillance involves monitoring participants for additional tumor growth after receiving cancer treatment. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether deferring surgery after active surveillance and chemotherapy will work better in treating participants with stage II-III rectal cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Chemotherapy
- OTHER Patient Observation
- PROCEDURE Resection of Rectum
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2026-10-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594630
The ClinicalTrials.gov registry entry for NCT03594630 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 117-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT03594630 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03594630 about?
NCT03594630 is a clinical study titled "Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer". This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer. Active surveillance involves monitoring participants for additional tumor growth after receiving cancer treatment. Drugs used in chemotherapy work in d...
What is the current status of trial NCT03594630?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 120 participants. The study started on 2024-03-13. Estimated completion is 2026-10-31.
What conditions does trial NCT03594630 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8.
What interventions are being tested in trial NCT03594630?
The interventions under investigation include: Questionnaire Administration (OTHER), Chemotherapy (DRUG), Patient Observation (OTHER), Resection of Rectum (PROCEDURE).
Who is sponsoring clinical trial NCT03594630?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03594630 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
-
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
RECRUITING
-
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.